BR112015008311A2 - conjugados fármaco-proteína - Google Patents

conjugados fármaco-proteína

Info

Publication number
BR112015008311A2
BR112015008311A2 BR112015008311A BR112015008311A BR112015008311A2 BR 112015008311 A2 BR112015008311 A2 BR 112015008311A2 BR 112015008311 A BR112015008311 A BR 112015008311A BR 112015008311 A BR112015008311 A BR 112015008311A BR 112015008311 A2 BR112015008311 A2 BR 112015008311A2
Authority
BR
Brazil
Prior art keywords
drug
conjugates
protein conjugates
protein
specific
Prior art date
Application number
BR112015008311A
Other languages
English (en)
Inventor
Godwin Antony
Badescu George
Burt John
Frigerio Mark
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of BR112015008311A2 publication Critical patent/BR112015008311A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo patente de invenção: "conjugados fármaco-proteína". a presente invenção refere-se a conjugados específicos, que contêm maitansinas e uma proteína ou um peptídeo de ligação, e a processos para sua fabricação que são descritos. os conjugados usam a tecnologia de um ligante específico que fornece vantagens com relação a conjugados anticorpo-fármaco conhecidos.
BR112015008311A 2012-10-24 2013-10-11 conjugados fármaco-proteína BR112015008311A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261717743P 2012-10-24 2012-10-24
PCT/GB2013/052662 WO2014064424A1 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Publications (1)

Publication Number Publication Date
BR112015008311A2 true BR112015008311A2 (pt) 2017-07-04

Family

ID=49488609

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008311A BR112015008311A2 (pt) 2012-10-24 2013-10-11 conjugados fármaco-proteína

Country Status (20)

Country Link
US (1) US20150283259A1 (pt)
EP (1) EP2911696B1 (pt)
JP (1) JP6328649B2 (pt)
KR (1) KR20150085808A (pt)
CN (1) CN104755106B (pt)
AU (1) AU2013336410B2 (pt)
BR (1) BR112015008311A2 (pt)
CA (1) CA2884359A1 (pt)
DK (1) DK2911696T3 (pt)
ES (1) ES2652513T3 (pt)
HK (1) HK1208186A1 (pt)
HU (1) HUE037604T2 (pt)
IL (1) IL237673A0 (pt)
IN (1) IN2015DN02577A (pt)
MX (1) MX2015005124A (pt)
NO (1) NO2789793T3 (pt)
RU (1) RU2015119557A (pt)
SG (1) SG11201501955VA (pt)
WO (1) WO2014064424A1 (pt)
ZA (1) ZA201501996B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570151B2 (en) 2013-03-15 2020-02-25 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
WO2014194030A2 (en) * 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2015031396A1 (en) 2013-08-26 2015-03-05 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
EP3145552B1 (en) * 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
CA2950155C (en) * 2014-06-02 2021-11-23 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
GB2531715A (en) * 2014-10-24 2016-05-04 Polytherics Ltd Novel drug conjugates
US10835616B2 (en) 2014-10-14 2020-11-17 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG
ES2960741T3 (es) * 2014-10-24 2024-03-06 Abzena Uk Ltd Conjugados y reactivos de conjugación
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3331569A1 (en) * 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017178828A1 (en) 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
WO2017212250A1 (en) 2016-06-06 2017-12-14 Polytherics Limited Antibodies, uses thereof and conjugates thereof
GB201615725D0 (en) * 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
KR20220029725A (ko) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
WO2022051591A2 (en) 2020-09-04 2022-03-10 Novarock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
CA3213295A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
CN117147824A (zh) * 2022-05-29 2023-12-01 菲鹏生物股份有限公司 一种抗体缀合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
BR122018071968B8 (pt) * 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
BRPI0617546A2 (pt) * 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
EP2211904B1 (en) * 2007-10-19 2016-08-17 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
EP2276506A4 (en) * 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
AR078471A1 (es) * 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
IN2014DN10428A (pt) * 2012-06-19 2015-08-21 Polytherics Ltd

Also Published As

Publication number Publication date
US20150283259A1 (en) 2015-10-08
AU2013336410A1 (en) 2015-04-09
HUE037604T2 (hu) 2018-09-28
SG11201501955VA (en) 2015-04-29
EP2911696B1 (en) 2017-09-20
AU2013336410B2 (en) 2017-08-03
WO2014064424A1 (en) 2014-05-01
CN104755106B (zh) 2018-03-13
IL237673A0 (en) 2015-04-30
ES2652513T3 (es) 2018-02-02
NO2789793T3 (pt) 2018-01-27
CN104755106A (zh) 2015-07-01
CA2884359A1 (en) 2014-05-01
KR20150085808A (ko) 2015-07-24
MX2015005124A (es) 2015-10-29
HK1208186A1 (en) 2016-02-26
JP2015536329A (ja) 2015-12-21
RU2015119557A (ru) 2016-12-20
JP6328649B2 (ja) 2018-05-23
ZA201501996B (en) 2016-01-27
IN2015DN02577A (pt) 2015-09-11
EP2911696A1 (en) 2015-09-02
DK2911696T3 (en) 2018-01-08

Similar Documents

Publication Publication Date Title
BR112015008311A2 (pt) conjugados fármaco-proteína
NZ754051A (en) Novel antibodies and uses thereof
EA201890315A1 (ru) Молекулы антител, связывающие cd22
BR112015021838A2 (pt) amatoxina, método de síntese, composição farmacêutica
BR112013005699A2 (pt) moléculas de ligação a 4-1bb
UA104585C2 (ru) Композиция, содержащая антитело, которое связывается с доменом ii her2, и его кислые варианты
MX2018000147A (es) Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45).
IN2015DN02349A (pt)
BR112014019611A2 (pt) agentes de ligação mica
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
UA113712C2 (xx) Антитіло до fap і способи його застосування
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
UA115402C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
BR112013021562A2 (pt) anticorpos para cd70
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
AU2016219704A1 (en) Anti-Notch1 antibodies
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
WO2013184912A3 (en) Binding agents that modulate the hippo pathway and uses thereof
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
NZ730450A (en) Binding molecules, especially antibodies, binding to l1cam (cd171)
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MX2016003490A (es) Analogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune.
UA99339C2 (ru) Антитело, которое специфично связывает человеческий tyrp1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/00 (2006.01)

B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]